×
S&P 500   4,148.20 (+2.23%)
DOW   33,141.92 (+1.55%)
QQQ   308.47 (+3.05%)
AAPL   149.03 (+3.65%)
MSFT   271.98 (+2.29%)
FB   195.09 (+1.81%)
GOOGL   2,242.63 (+4.03%)
AMZN   2,289.04 (+3.04%)
TSLA   758.04 (+7.11%)
NVDA   188.58 (+5.64%)
BABA   93.06 (-1.50%)
NIO   16.51 (+2.99%)
AMD   102.25 (+3.54%)
CGC   4.86 (-12.43%)
MU   73.34 (+3.88%)
T   21.22 (-0.47%)
GE   78.42 (+1.83%)
F   13.59 (+3.58%)
DIS   109.28 (+3.48%)
AMC   14.42 (+17.91%)
PFE   53.62 (-0.69%)
PYPL   85.31 (+6.08%)
NFLX   194.67 (+1.71%)
S&P 500   4,148.20 (+2.23%)
DOW   33,141.92 (+1.55%)
QQQ   308.47 (+3.05%)
AAPL   149.03 (+3.65%)
MSFT   271.98 (+2.29%)
FB   195.09 (+1.81%)
GOOGL   2,242.63 (+4.03%)
AMZN   2,289.04 (+3.04%)
TSLA   758.04 (+7.11%)
NVDA   188.58 (+5.64%)
BABA   93.06 (-1.50%)
NIO   16.51 (+2.99%)
AMD   102.25 (+3.54%)
CGC   4.86 (-12.43%)
MU   73.34 (+3.88%)
T   21.22 (-0.47%)
GE   78.42 (+1.83%)
F   13.59 (+3.58%)
DIS   109.28 (+3.48%)
AMC   14.42 (+17.91%)
PFE   53.62 (-0.69%)
PYPL   85.31 (+6.08%)
NFLX   194.67 (+1.71%)
S&P 500   4,148.20 (+2.23%)
DOW   33,141.92 (+1.55%)
QQQ   308.47 (+3.05%)
AAPL   149.03 (+3.65%)
MSFT   271.98 (+2.29%)
FB   195.09 (+1.81%)
GOOGL   2,242.63 (+4.03%)
AMZN   2,289.04 (+3.04%)
TSLA   758.04 (+7.11%)
NVDA   188.58 (+5.64%)
BABA   93.06 (-1.50%)
NIO   16.51 (+2.99%)
AMD   102.25 (+3.54%)
CGC   4.86 (-12.43%)
MU   73.34 (+3.88%)
T   21.22 (-0.47%)
GE   78.42 (+1.83%)
F   13.59 (+3.58%)
DIS   109.28 (+3.48%)
AMC   14.42 (+17.91%)
PFE   53.62 (-0.69%)
PYPL   85.31 (+6.08%)
NFLX   194.67 (+1.71%)
S&P 500   4,148.20 (+2.23%)
DOW   33,141.92 (+1.55%)
QQQ   308.47 (+3.05%)
AAPL   149.03 (+3.65%)
MSFT   271.98 (+2.29%)
FB   195.09 (+1.81%)
GOOGL   2,242.63 (+4.03%)
AMZN   2,289.04 (+3.04%)
TSLA   758.04 (+7.11%)
NVDA   188.58 (+5.64%)
BABA   93.06 (-1.50%)
NIO   16.51 (+2.99%)
AMD   102.25 (+3.54%)
CGC   4.86 (-12.43%)
MU   73.34 (+3.88%)
T   21.22 (-0.47%)
GE   78.42 (+1.83%)
F   13.59 (+3.58%)
DIS   109.28 (+3.48%)
AMC   14.42 (+17.91%)
PFE   53.62 (-0.69%)
PYPL   85.31 (+6.08%)
NFLX   194.67 (+1.71%)
NASDAQ:SRRA

Sierra Oncology (SRRA) Stock Forecast, Price & News

$54.76
+0.03 (+0.05%)
(As of 05/27/2022 03:23 PM ET)
Add
Compare
Today's Range
$54.75
$54.78
50-Day Range
$32.05
$54.75
52-Week Range
$14.91
$54.97
Volume
6,716 shs
Average Volume
1.06 million shs
Market Capitalization
$1.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.01
30 days | 90 days | 365 days | Advanced Chart
Receive SRRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Sierra Oncology and its competitors with MarketBeat's FREE daily newsletter.

Sierra Oncology logo

About Sierra Oncology

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRRA
Previous Symbol
NASDAQ:DNAI
Fax
N/A
Employees
109
Year Founded
N/A

Sales & Book Value

Annual Sales
$300 thousand
Book Value
$10.71 per share

Profitability

Net Income
$-94.66 million
Pretax Margin
-43,527.50%

Debt

Price-To-Earnings

Miscellaneous

Free Float
7,892,000
Market Cap
$1.34 billion
Optionable
Optionable

Company Calendar

Last Earnings
3/10/2022
Today
5/27/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.08 out of 5 stars

Medical Sector

490th out of 1,424 stocks

Pharmaceutical Preparations Industry

216th out of 681 stocks

Analyst Opinion: 1.1Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -













Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions

Is Sierra Oncology a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sierra Oncology in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Sierra Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SRRA, but not buy additional shares or sell existing shares.
View analyst ratings for Sierra Oncology
or view top-rated stocks.

When is Sierra Oncology's next earnings date?

Sierra Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Sierra Oncology
.

How were Sierra Oncology's earnings last quarter?

Sierra Oncology, Inc. (NASDAQ:SRRA) issued its quarterly earnings results on Thursday, March, 10th. The biotechnology company reported ($1.67) EPS for the quarter, missing the consensus estimate of ($1.60) by $0.07.
View Sierra Oncology's earnings history
.

What price target have analysts set for SRRA?

5 brokers have issued 12-month price targets for Sierra Oncology's stock. Their forecasts range from $39.00 to $55.00. On average, they expect Sierra Oncology's stock price to reach $51.00 in the next twelve months. This suggests that the stock has a possible downside of 6.9%.
View analysts' price targets for Sierra Oncology
or view top-rated stocks among Wall Street analysts.

Who are Sierra Oncology's key executives?
Sierra Oncology's management team includes the following people:
  • Dr. Stephen George Dilly M.B.B.S, Pres, CEO & Director (Age 62, Pay $1.02M) (LinkedIn Profile)
  • Mr. Sukhi Jagpal CPA, CA, CBV, CPA, M.B.A., MBA, Chief Financial Officer (Age 48, Pay $648.02k)
  • Dr. Barbara J. Klencke M.D., Chief Medical Officer (Age 65, Pay $773.39k)
  • Ms. Christina Thomson J.D., M.S., Gen. Counsel, Chief Compliance Officer & Sec. (Age 51)
  • Mr. William D. Turner, Chief Regulatory & Technical Operations Officer (Age 56) (LinkedIn Profile)
  • Mr. Kevin Norrett M.B.A., M.S., Chief Bus. Officer (Age 49)
What other stocks do shareholders of Sierra Oncology own?
What is Sierra Oncology's stock symbol?

Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA."

Who are Sierra Oncology's major shareholders?

Sierra Oncology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Frazier Life Sciences Management L.P. (9.59%), Rock Springs Capital Management LP (4.81%), Paradigm Biocapital Advisors LP (3.16%), BlackRock Inc. (1.84%), Silverarc Capital Management LLC (1.82%) and Goldman Sachs Group Inc. (1.81%). Company insiders that own Sierra Oncology stock include Barbara Klencke, Craig A Collard, Gaurav Aggarwal, Llp Abingworth, Longitude Capital Partners Iii, Mary Christina Thomson, Stephen George Dilly and William D Turner.
View institutional ownership trends for Sierra Oncology
.

Which institutional investors are selling Sierra Oncology stock?

SRRA stock was sold by a variety of institutional investors in the last quarter, including Frazier Management LLC, Renaissance Technologies LLC, Rock Springs Capital Management LP, Royal Bank of Canada, and Northern Trust Corp. Company insiders that have sold Sierra Oncology company stock in the last year include Mary Christina Thomson, and William D Turner.
View insider buying and selling activity for Sierra Oncology
or view top insider-selling stocks.

Which institutional investors are buying Sierra Oncology stock?

SRRA stock was acquired by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., Goldman Sachs Group Inc., BlackRock Inc., Paradigm Biocapital Advisors LP, Silverarc Capital Management LLC, Kynam Capital Management LP, J. Goldman & Co LP, and Parkman Healthcare Partners LLC. Company insiders that have bought Sierra Oncology stock in the last two years include Barbara Klencke, Craig A Collard, Gaurav Aggarwal, Llp Abingworth, Longitude Capital Partners Iii, and Stephen George Dilly.
View insider buying and selling activity for Sierra Oncology
or or view top insider-buying stocks.

How do I buy shares of Sierra Oncology?

Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sierra Oncology's stock price today?

One share of SRRA stock can currently be purchased for approximately $54.76.

How much money does Sierra Oncology make?

Sierra Oncology has a market capitalization of $1.34 billion and generates $300 thousand in revenue each year. The biotechnology company earns $-94.66 million in net income (profit) each year or ($6.77) on an earnings per share basis.

How many employees does Sierra Oncology have?

Sierra Oncology employs 109 workers across the globe.

What is Sierra Oncology's official website?

The official website for Sierra Oncology is www.sierraoncology.com.

How can I contact Sierra Oncology?

Sierra Oncology's mailing address is 2150-885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company can be reached via phone at (604) 558-6536 or via email at [email protected].

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.